We have to send the verification link to your mailbox, please check and verify
Did not receive verification mail? Please confirm whether the mailbox is correct or not Re send mail
Determine

4th China Pharma IP Summit 2019

De

2019-05-17 11:36:20

3.jpg


Time: October 23-25, 2019

Location: Primus Hotel Shanghai Hongqiao

Theme: IP Challenges & Strategy for Global Pharma Innovation

We are glad to inform you 4th China Pharma IP Summit 2019 is officially launched. This year the event will be hold on 23-25, October for 3 days at Primus Hotel Shanghai Hongqiao.


CPIPS has been well organized for past three years with more than 1000 Pharma IP Leaders from Global Pharma/Biotech Companies, Law Firms  and Government Agencies. Lot of hot topics In Pharma IP area were discussed. This year would be more interesting for IP peers with the 4th China Patent Law Amendment which may take effect in 2019 and BREXIT, UPC and Unitary Patent in Europe as well as hot issues and updates from US, Japan India and Korea.As a dedicated event to Pharmaceutical Intellectual Property Protection, we will continue to provide a high quality networking platform for you and your colleagues, discussing hot issues and networking with your partners.


Conference Background:Since May 2017, China Food and Drug Administration, the General Office of the Central Committee of the Communist party of China and the General Office of State Council have successively issued the Regarding the Solicitation of Related Policies on encouraging the Protection of Drugs and Medical Devices Innovation and protecting the rights and interests of innovators (Consultation Draft) and the Opinions on deepening the reform of the review and approval system and encouraging pharmaceuticals and medical device innovation. These polices make deployment for advancing the reform of the examination and approval system for pharmaceuticals and medical devices and promoting of the adjustment of industrial structure and technological innovation, which clarified the establishment of drug Patent Linkage System, the development of pilot projects on Pharmaceutical Patent Term Compensation System and improvement and implement of Pharmaceutical Regulatory Data Protection Systems and other pharmaceutical innovation positive measures. On December 5, 2018, the State Council executive meeting adopted the Amendment of the Patent Law of the People's Republic of China (Draft) and consulted with the public on January 4, 2019. Relevant persons pointed out that the revision of the Patent Law is an important part of promoting the implementation of the relevant supporting rules of the Drug Registration System. The Pharmaceutical Experimental Data Protection System, the Patent Term Compensation, and the Patent Linkage System are expected to be improved , clarified and implemented with the revision of the Patent Law. At the same time, along with accelerating the construction of a strong IP country and promoting the reform and development of relevant IP field, on January 1, 2019, the IP Court of the Supreme People's Court was unveiled in Beijing, which further strengthen the judicial protection of IP in China and provide a strong judicial guarantee for China to create a medical innovation environment and promote the innovation and development of domestic and foreign pharmaceutical companies.


On the other hand, with the rapid development of pharmaceutical industry in the world, China officially joined ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) in 2017 and participate in the global competition in line with the highest international standards. In 2018, the FDA of US approved the listing of 59 new molecular entities, breaking the historical record that had been dormant for many years. In China, National Medical Products


Administration (NMPA) has also approved the listing of 48 new drugs as never before. Of the 48 new drugs, 38 are imported and 10 are domestically produced. Enter of foreign pharmaceutical companies, going out of Chinese pharmaceutical companies, and commercial cooperation between domestic and foreign pharmaceutical companies, the increase in patent applications, patent authorization, patent infringements, invalid litigation, and technology transfer have made IP protection such as patents, trade secrets, and trademarks, and the cultivation of high-value patents and risk prevention become the focus of pharmaceutical companies. The pharmaceutical field is one of the most interdependent technical areas on IP protection, especially patent protection. Familiarity with IP protection policies, Drug Regulatory Systems, patent examination standards and differences, and the judicial and administrative procedures for IP protection in major countries and regions and emerging markets around the world, improving IP Management System, standardizing IP System of enterprises, improving IP protection of core technologies, and strengthening abroad layout of IP are the basis for improving domestic and foreign pharmaceutical companies to participate in global competition.


In this context, 4th China Pharmaceutical IP Summit 2019(CPIPS2019)will continue to build high-quality, high-participation, high-time international cooperation, learning, sharing and exchange platforms for domestic and foreign pharmaceutical IP practitioners. The summit invites domestic and foreign pharmaceutical IP practitioners to discuss the dynamics of industry regulatory policies, hot and difficult issues, case analysis, corporate practice experience and development trends. In this way, it promotes industry exchanges and interactions and promotes the innovative development of China's biomedical industry.


CPIPS 2019 Conference Structure :


微信截图_20190517112543.png


Through this year event, you will have opportunity to:

  • Following the latest development of China Patent Law Amendment, Patent Linkage, Patent Term Extension reform , and related Drug Regulatory Updates in China.

  • Addressing Challenges and Uncertainties under Brexit, Unitary Patent & UPC in Europe.

  • Understanding the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.

  • Learning IP management and practical experiences from Global and China leading pharma companies.

  • Meeting your clients/partners face to face and interact with industry peers.


Latest Confirmed Speakers with Topics:


1: Identifying the Loss of Exclusivity (LoE) of a U.S. Pharmaceutical Patent Portfolio

  • The LoE date

  • Factors that can increase term: PTA and PTE

  • Factors that can reduce term: obviousness-type double patenting and terminal disclaimers

  • Interplay with FDA regulatory exclusivities

  • Assessing LoE in a complex pharmaceutical patent portfolio

Carl A. Morales, Partner, Dechert LLP


2: Patent System for Pharmaceutical Invention in South Korea

  • Tips for obtaining a pharmaceutical patent in Korea

  • Patent term extension in Korea since 1987

  • Patent-approval linkage system in Korea since 2015

  • Recent key decisions rendered by the Korean Supreme Court

Ilseok Alban Kang, Patent Attorney, FirstLaw P. C.


3: Patent System and Practice of Medical Fields and Patent Term Extension in Japan

  • Introduction of Japanese patent examination guidelines on medical field, focused on “patent subject matter eligibility of medical invention” and “novelty and inventive step of medical invention” with case examples.

  • Patent term extension system in Japan

  • Recent IP issues in JPO

Toru Matsuoka, Deputy Director, Examination Standards Office in JPO


4:UPC and UPS  - Why does it Make Sense for Europe and What Could be the Impact of Brexit?

  • Why – if at all – is Brexit a problem for the UPC/UPS

  • Determining whether the UK can still participate in the UPC after its exit from EU?

  • How does this affect pharma companies seeking patent protection in the U.K?

  • How will this impact patent prosecution strategies for pharmaceutical companies looking to obtain Unitary Patents?

  • How are we targeting the new Courts – how will Bayer use it?

  • Why is Bayer in favour of the new system?

Dr. Jörg Thomaier, Head of IP, Bayer Group


5: How to Build a Successful Licensing Program and Other Strategies for IP Monetization

  • Developing a systematic approach to successful patent Licensing

  • Portfolio evaluation & management.

  • How do you value IP?

  • Enforcement & monetization

  • Creating a strategic licensing plan

Peter L. Dolan,  Strategy and Business Development Senior Director, Sanofi


6: Panel Discussion: Evaluation of Inventive Step of Pharmaceutical Compound Inventions

Moderator:

Wenping Chen, Partner, King & Wood Mallesons

Panelist:

Tina Tai, Partner,King & Wood Mallesons

Innovative Pharma Company

Beijing IP Court


Latest Confirmed Speakers :

Carl A. Morales, Partner, Dechert LLP

Dr. Jörg Thomaier, Head of IP, Bayer Group

Feng Xu, IP Director for China and Asia, AstraZeneca

Tina Tai, Partner, King & Wood Mallesons

Ilseok Alban Kang, Patent Attorney, FirstLaw P. C.

Daisy Wu, IP Director, Shanghai Henlius Biotech,Inc.

Gustavo Morais, Partner, IP Agent, Dannemann Siemsen

Dr. Christof Bull, Associate General Patent Counsel, UCB Biopharma

Yongshun Cheng, Director, Beijing Intellectual Property Institute

Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP

Yang Xu, Assistant General Counsel, Intellectual Property, BeiGene, Ltd.

Peter L. Dolan, Strategy and Business Development Senior Director, Sanofi

Dr. Poonam Raghuvanshi, Vice President & Head of IP, Dr. Reddy's Laboratories Ltd

Michael Wise, Partner, Chair of the Life Sciences & Healthcare industry sector, Perkins Coie LLP

He Wei, Director of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA

Hou Yao, Researcher of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA


Main Topics will be Discussed:

  • Global Pharma Innnovation, IP Issues and Access to Medicines

  • Interpretation: The Latest Drug Regulatory Policies and Implementing Details from National Medical Products Administration

  • The Significance and Influence of China Patent Law Amendment

  • The Present Situation & Trends of Patent Examination and Hotspot Issues in Reexamination and Invalidation Cases in China

  • IP Challenges and Strategy from Perspective of Innovative Pharma Company under New Environment in China

  • Case Study from Hengrui Medicine on High Value Patent Cultivation & IP Management

  • Hot Issues and Difficulties in Pharma Patent Infringement Litigation Cases

  • Issues on Patent Licensing and Technology Transfer

  • USPTO Patent Examination Practices and Updated Guidance

  • Latest Developments of IPR and Recent Patent Invalidation Cases

  • The Strategy of ANDA Filers to Challenge Patents Under a PIV Certification and Recent ANDA Litigation Cases Study

  • Biosimilars in US,EU and China: Where Are We Now and Where Are We Going?

  • IP Considerations & Strategies When Entering the U.S. Market and Challenges & Impacts Under Sino-US Trade Friction

  • Updates from EPO in Pharma & Biotech Area

  • UK Pharma Perspective on IP Protection and Strategy

  • IP Challenges and Strategy for Patent Applicants and Patentees before and after the UPC Agreement comes into Effect

  • Partnering of European and Chinese Pharma: IP Management and Strategy for Cross Border licensing

  • Updates and Strategy of Pharma IP Protection in Japan

  • IP Management and Case Study from India Leading Generic Company

  • Pharma Patent System and Examination Practice in South Korea

  • Traditional Chinese Medicine: Development Status ,Challenges & Opportunities

  • Current Patenting Situation of Chinese Medicine in China & Analysis from Reexamination and Invalidation Cases

  • Chinese Medicine Variety Protection Status and Challenges

  • IP Challenges and Strategy for Chinese Medicine ‘Going Out’


About Organizer:

Shanghai YIP Events was founded in August of 2014, an international events organizer in industry’s segment areas. YIP Events now focusing on Chemical industry and Pharma/Life science industry by organizing high level international conferences to promote industry development, explore the challenges and opportunities of the industry and establish platform for the industry peers to networking, learning and sharing.


China Pharma IP Summit (CPIPS) is the the largest IP event focused on pharma industry in China. CPIPS is devoted to raise the level in IP management of pharmaceutical industry in China and drive pharmaceutical R&D and innovation. We started CPIPS from 2016 and it has been held three times continuously, and gathering around 1000 attendees from relevant government departments, industry associations, pharmaceutical/biotechnology companies, law firms, IP agencies, IP solution providers and so on. Our topics covered the protection and evaluation of IP all over the world, include China, Europe, US, Japan & Korea, India and so on. We hope CPIPS could be a good networking platform for IP leaders of Pharma Industry and promote industry cooperation.


Contact us for more information:

Johnson Li

Conference Manager

Tel: 86 21 6142 1083

Mobile: 86 189 1779 8290

Email: Johnson.Leung@yipevents.com



Source:IPRdaily(iprdaily.com)

Editor:De

    I also said the two sentence
    Also you can enter 140words
    I want to comment.
    Reply
    Also you can enter 70 words